NCT05104762View on ClinicalTrials.gov

IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

March 2, 2022

Study Completion Date

March 3, 2023

Conditions
Guillain-Barre Syndrome
Interventions
DEVICE

plasmapheresis device

Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)

DRUG

Intravenous immunoglobulin

group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.

Trial Locations (1)

Unknown

Assiut university, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT05104762 - IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients | Biotech Hunter | Biotech Hunter